JP2015535239A - 抗腫瘍性および抗増殖性の薬剤としての１−（置換スルホニル）−２−アミノイミダゾリンの誘導体 - Google Patents

抗腫瘍性および抗増殖性の薬剤としての１−（置換スルホニル）−２−アミノイミダゾリンの誘導体 Download PDF

Info

Publication number
JP2015535239A
JP2015535239A JP2015538627A JP2015538627A JP2015535239A JP 2015535239 A JP2015535239 A JP 2015535239A JP 2015538627 A JP2015538627 A JP 2015538627A JP 2015538627 A JP2015538627 A JP 2015538627A JP 2015535239 A JP2015535239 A JP 2015535239A
Authority
JP
Japan
Prior art keywords
dihydro
imidazol
amine
sulfonyl
indoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015538627A
Other languages
English (en)
Japanese (ja)
Inventor
ヴィエスワフ ピクル スタニスワフ
ヴィエスワフ ピクル スタニスワフ
マレック コロディ ヴィエスワフ
マレック コロディ ヴィエスワフ
Original Assignee
オンコアレンディ セラピューティクス エスピー ゼット オー オー
オンコアレンディ セラピューティクス エスピー ゼット オー オー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコアレンディ セラピューティクス エスピー ゼット オー オー, オンコアレンディ セラピューティクス エスピー ゼット オー オー filed Critical オンコアレンディ セラピューティクス エスピー ゼット オー オー
Publication of JP2015535239A publication Critical patent/JP2015535239A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C07C247/06—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015538627A 2013-04-10 2014-03-27 抗腫瘍性および抗増殖性の薬剤としての１−（置換スルホニル）−２−アミノイミダゾリンの誘導体 Pending JP2015535239A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361810276P 2013-04-10 2013-04-10
PLPL403491 2013-04-10
US61/810,276 2013-04-10
PL403491A PL231063B1 (pl) 2013-04-10 2013-04-10 Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe
PCT/IB2014/060200 WO2014167446A1 (en) 2013-04-10 2014-03-27 Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agents

Publications (1)

Publication Number Publication Date
JP2015535239A true JP2015535239A (ja) 2015-12-10

Family

ID=51662842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538627A Pending JP2015535239A (ja) 2013-04-10 2014-03-27 抗腫瘍性および抗増殖性の薬剤としての１−（置換スルホニル）−２−アミノイミダゾリンの誘導体

Country Status (9)

Country Link
US (2) US9095575B2 (enExample)
EP (1) EP2875017A1 (enExample)
JP (1) JP2015535239A (enExample)
CN (1) CN104619697A (enExample)
AU (1) AU2014252281A1 (enExample)
CA (1) CA2883014A1 (enExample)
IN (1) IN2015KN00569A (enExample)
PL (1) PL231063B1 (enExample)
WO (1) WO2014167446A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023543140A (ja) * 2020-08-31 2023-10-13 ビューポイント セラピューティクス， インコーポレイテッド 眼疾患を治療するための化合物および製剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
US12528792B2 (en) 2019-10-15 2026-01-20 TroBio Therapeutics Pty Ltd Sulfonamide compounds and the use thereof in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505096A (ja) * 1996-08-22 2000-04-25 同和薬品工業株式會社 抗腫瘍剤としてのアリールスルホニルイミダゾロン誘導体
WO2006106812A1 (ja) * 2005-03-31 2006-10-12 Astellas Pharma Inc. プロパン-1,3-ジオン誘導体又はその塩

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS97860B5 (enExample) * 1959-09-04 1960-12-15
US3538085A (en) 1966-03-24 1970-11-03 Geigy Chem Corp 1-phenylsulfonyl-2-imino-imidazolidines and hexahydropyrimidines
CH470397A (de) 1966-03-24 1969-03-31 Geigy Ag J R Verfahren zur Herstellung neuer Derivate des Sulfanilamids
AU6578090A (en) 1989-11-06 1991-05-09 Warner-Lambert Company Acat inhibitors
US6184242B1 (en) 1997-09-04 2001-02-06 Syntex Usa (Llc) 2-(substituted-phenyl)amino-imidazoline derivatives
US20040019092A1 (en) 2001-11-14 2004-01-29 Daniel Berney Non-peptide somatostatin receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505096A (ja) * 1996-08-22 2000-04-25 同和薬品工業株式會社 抗腫瘍剤としてのアリールスルホニルイミダゾロン誘導体
WO2006106812A1 (ja) * 2005-03-31 2006-10-12 Astellas Pharma Inc. プロパン-1,3-ジオン誘導体又はその塩

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016011146; ＳＨＡＲＭＡ，Ｖ．Ｋ．　ｅｔ　ａｌ: 'Ｉｍｐｏｒｔａｎｃｅ　ｏｆ　ｉｍｉｄａｚｏｌｉｄｉｎｏｎｅ　ｍｏｔｉｆ　ｉｎ　４-ｐｈｅｎｙｌ-Ｎ-ａｒｙｌｓｕｌｆｏｎｙｌｉｍｉｄａｚｏｌｉｄｉｎｏｎｅ　ｆｏｒ　ｔｈｅｉｒ　ａｎｔｉｃａｎｃｅｒ　ａ' Ｂｕｌｌｅｔｉｎ　ｏｆ　ｔｈｅ　Ｋｏｒｅａｎ　Ｃｈｅｍｉｃａｌ　Ｓｏｃｉｅｔｙ Ｖｏｌ．３２，　Ｎｏ．８, 2011, ｐ．３００９-３０１６ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023543140A (ja) * 2020-08-31 2023-10-13 ビューポイント セラピューティクス， インコーポレイテッド 眼疾患を治療するための化合物および製剤
JP7801312B2 (ja) 2020-08-31 2026-01-16 ビューポイント セラピューティクス， インコーポレイテッド 眼疾患を治療するための化合物および製剤
US12637425B2 (en) 2020-08-31 2026-05-26 Visus Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases

Also Published As

Publication number Publication date
PL231063B1 (pl) 2019-01-31
CN104619697A (zh) 2015-05-13
EP2875017A1 (en) 2015-05-27
CA2883014A1 (en) 2014-10-16
IN2015KN00569A (enExample) 2015-07-17
WO2014167446A1 (en) 2014-10-16
US8981114B2 (en) 2015-03-17
US9095575B2 (en) 2015-08-04
AU2014252281A1 (en) 2015-04-02
US20140309259A1 (en) 2014-10-16
PL403491A1 (pl) 2014-10-13
US20140309240A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
TWI791511B (zh) 細胞凋亡誘導劑
CN110177788A (zh) 作为bcl-2选择性凋亡诱导剂的化合物
WO2023284838A1 (zh) Aak1抑制剂及其用途
EA006711B1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
TW202144369A (zh) 海鞘素類衍生物及其製備方法與醫藥用途
WO2012112674A2 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014086102A1 (zh) 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
TWI752026B (zh) 一類蛋白激酶抑制劑
US20170174687A1 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
US8981114B2 (en) Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agents
CN110078730B (zh) 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
CN110467610A (zh) 一种取代嘧啶化合物、其制备方法和用途
CN103509030A (zh) 喜树碱类化合物及其制备和用途
CN108101889A (zh) 氘代n-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
CN103172577B (zh) 4-氨基喹唑啉及4-氨基喹啉类化合物及其用途
CN108017633A (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CA3191714A1 (en) Benzylamine derivative, preparation method therefor and use thereof
JP2019522651A (ja) タンパク質キナーゼ阻害剤としての置換されているピロロ［２，３−ｄ］ピリダジン−４−オン及びピラゾロ［３，４−ｄ］ピリダジン−４−オン
TW202028199A (zh) 作為蛋白激酶抑制劑的萘啶酮和吡啶基嘧啶酮類化合物
CN112759583B (zh) 包含呋喃基的喹啉类衍生物及其制备方法和用途
JPWO2010032731A1 (ja) 結晶態様のベンゾイミダゾール化合物又はその塩
JP2019510780A (ja) 癌治療用ｌｌｓ化合物
CA3071900A1 (en) Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161025